RedHill Biopharma (RDHL) Cost of Revenue (2014 - 2023)

RedHill Biopharma (RDHL) has 8 years of Cost of Revenue data on file, last reported at $806000.0 in Q2 2023.

• On a quarterly basis, Cost of Revenue fell 91.04% year-over-year to $806000.0 in Q2 2023; TTM through Jun 2023 was $20.5 million, a 53.33% decrease from a year earlier, with the FY2025 full-year figure at -$5.2 million, down 100.0% from the prior year.
• Cost of Revenue for Q2 2023 stood at $806000.0, down from $1.6 million in the prior quarter.
• Over the last five years, Cost of Revenue for RDHL reached as high as $19.3 million in Q4 2021 and fell as low as $417000.0 in Q1 2019.
• Historically, Cost of Revenue has averaged $6.9 million across 5 years, with a median of $8.8 million in 2022.
• Across the five-year window, Cost of Revenue jumped 3238.35% in 2020 and plunged 91.04% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $788000.0 in 2019, then surged by 1251.78% to $10.7 million in 2020, then surged by 81.51% to $19.3 million in 2021, then sank by 55.53% to $8.6 million in 2022, then plunged by 90.63% to $806000.0 in 2023.
• Per Business Quant data, the three most recent Cost of Revenue figures were $806000.0 in Q2 2023, $1.6 million in Q1 2023, and $8.6 million in Q4 2022.